               SEQUENCE LISTING

<110> 21C Bio

<120> VACCINE TO PATHOGENIC IMMUNE ACTIVATION CELLS DURING INFECTIONS

<130> CV-1217/PCT

<150> EP 19189405.4
<151> 2019-07-31
<150> US 62/821774
<151> 2019-03-21
<150> US 16/360876
<151> 2019-03-21

<160> 17

<170> BiSSAP 1.3.6

<210> 1
<211> 9
<212> PRT
<213> Artificial Sequence


<220> 
<223> MHCIb/E-binding antigen

<400> 1
Arg Met Tyr Ser Pro Val Ser Ile Leu 
1               5                   

<210> 2
<211> 9
<212> PRT
<213> Artificial Sequence


<220> 
<223> MHCIb/E-binding antigen

<400> 2
Pro Glu Ile Val Ile Tyr Asp Tyr Met 
1               5                   

<210> 3
<211> 9
<212> PRT
<213> Artificial Sequence


<220> 
<223> MHCIb/E-binding antigen

<400> 3
Thr Ala Leu Ser Glu Gly Ala Thr Pro 
1               5                   

<210> 4
<211> 9
<212> PRT
<213> Artificial Sequence


<220> 
<223> MHCIb/E-binding antigen

<400> 4
Arg Ile Arg Thr Trp Lys Ser Leu Val 
1               5                   

<210> 5
<211> 9
<212> PRT
<213> Artificial Sequence


<220> 
<223> CMV-derived peptide

<400> 5
Val Met Ala Pro Arg Thr Leu Ile Leu 
1               5                   

<210> 6
<211> 9
<212> PRT
<213> Artificial Sequence


<220> 
<223> CMV-derived peptide

<400> 6
Val Met Ala Pro Arg Thr Leu Val Leu 
1               5                   

<210> 7
<211> 15
<212> PRT
<213> Artificial Sequence


<220> 
<223> HLA-DR-restricted p24 antigen

<400> 7
Gln Gly Gln Met Val His Gln Ala Ile Ser Pro Arg Thr Leu Asn 
1               5                   10                  15  

<210> 8
<211> 15
<212> PRT
<213> Artificial Sequence


<220> 
<223> HLA-DR-restricted p24 antigen

<400> 8
Gly Glu Ile Tyr Lys Arg Trp Ile Ile Leu Gly Leu Asn Lys Ile 
1               5                   10                  15  

<210> 9
<211> 15
<212> PRT
<213> Artificial Sequence


<220> 
<223> HLA-DR-restricted p24 antigen

<400> 9
Lys Arg Trp Ile Ile Leu Gly Leu Asn Lys Ile Val Arg Met Tyr 
1               5                   10                  15  

<210> 10
<211> 15
<212> PRT
<213> Artificial Sequence


<220> 
<223> HLA-DR-restricted RT antigen

<400> 10
Phe Arg Lys Tyr Thr Ala Phe Thr Ile Pro Ser Ile Asn Asn Glu 
1               5                   10                  15  

<210> 11
<211> 6
<212> PRT
<213> Artificial Sequence


<220> 
<223> Claudin 4-binding peptide

<400> 11
Cys Thr Gly Lys Ser Cys 
1               5       

<210> 12
<211> 4
<212> PRT
<213> Artificial Sequence


<220> 
<223> Claudin 4-binding peptide

<400> 12
Leu Arg Val Gly 
1               

<210> 13
<211> 9
<212> PRT
<213> Artificial Sequence


<220> 
<223> Claudin 4-binding peptide

<400> 13
Cys Lys Ser Thr His Pro Leu Ser Cys 
1               5                   

<210> 14
<211> 9
<212> PRT
<213> Artificial Sequence


<220> 
<223> EBV derived peptide

<400> 14
Ser Gln Ala Pro Leu Pro Cys Val Leu 
1               5                   

<210> 15
<211> 9
<212> PRT
<213> Artificial Sequence


<220> 
<223> MBt derived peptide

<400> 15
Val Met Ala Thr Arg Arg Asn Val Leu 
1               5                   

<210> 16
<211> 9
<212> PRT
<213> Artificial Sequence


<220> 
<223> HIV-1 Pol derived peptide

<400> 16
Pro Glu Ile Val Ile Tyr Asp Tyr Met 
1               5                   

<210> 17
<211> 9
<212> PRT
<213> Artificial Sequence


<220> 
<223> HIV-1 Pol derived peptide

<400> 17
Arg Ile Arg Thr Trp Lys Ser Leu Val 
1               5                   

